Phase I Study of Colistin Methanesulfonate Sodium (CMS-Na) - A Randomized, Double Blind, Placebo Controlled, Single and Repeat Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CMS-Na in Healthy Japanese Male Subjects.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Colistimethate sodium (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 21 Jul 2017 Biomarkers information updated
- 14 Oct 2011 Results published in the Current Medical Research and Opinion.
- 13 Oct 2011 New trial record